BPC-157 vs TB-500: A Research Comparison

BPC-157 and TB-500 are two research peptides investigated for roles in tissue repair, but they are chemically and biologically distinct. BPC-157 is a synthetic 15-amino-acid partial sequence (GEPPPGKPADDAGLV) derived from a fragment of a gastric juice protein, studied in preclinical animal and cell models. TB-500 as sold on the research-supply market is most commonly the N-terminally acetylated 7-residue fragment Ac-LKKTETQ, taken from the central actin-binding region of thymosin beta-4 (Tβ4). TB-500 and full-length Tβ4 are related but not the same molecule, and the literature must be read with that distinction in mind.

Updated August 29, 2026 · Peptide Research Guides · ~10 min read

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic peptide with the 15-residue sequence GEPPPGKPADDAGLV, described as a partial sequence from a protein isolated from human gastric juice. It is studied in preclinical animal and cell models for cytoprotective and pro-angiogenic effects, with reported observations across gastrointestinal, tendon, ligament, muscle, and vascular models. The primary published literature is preclinical, human clinical data remain limited, and BPC-157 is not an approved drug in the United States.

What Is TB-500?

TB-500 is a research-supply designation, not a formal chemistry name, and it is important to be precise about what a given TB-500 vial actually contains. Most TB-500 product available through peptide-research suppliers is the N-terminally acetylated 7-residue fragment Ac-LKKTETQ, corresponding to the central actin-binding region (residues 17–23) of thymosin beta-4 (Tβ4). Some catalogs also sell the unmodified 7-residue fragment LKKTETQ. Neither is identical to full-length Tβ4, which is a 43-residue naturally occurring peptide. A TB-500 vial’s Certificate of Analysis should name the exact chemical species and molecular weight so the identity is not ambiguous.

BPC-157 vs TB-500: Side-by-Side

Attribute	BPC-157	TB-500 (as commonly sold: Ac-LKKTETQ)
Origin	Partial sequence of a human gastric-juice protein	Synthetic fragment (residues 17–23) of thymosin beta-4, typically N-terminally acetylated
Length	15 amino acids	7 amino acids (fragment); full-length Tβ4 itself is 43 aa
Sequence	GEPPPGKPADDAGLV	Ac-LKKTETQ (unmodified parent: LKKTETQ)
Approx. molecular weight	~1,419 Da	~889 Da for Ac-LKKTETQ; ~846 Da for the unmodified LKKTETQ
Not identical to	—	Full-length Tβ4 (~4.9 kDa, 43 aa)
Primary areas of preclinical research	Angiogenesis and cytoprotection in tendon, muscle, gastric, and vascular models	Actin sequestration and cell migration in the Tβ4 literature; the short fragment is used as a proxy in a subset of studies
Signalling / mechanism reported	Associations with VEGFR2 expression and VEGFR2-Akt-eNOS signalling in specific animal models; nitric-oxide-related pathways; growth-factor cross-talk	Actin binding is the established biochemical role of the Tβ4 parent; how much of that activity the short Ac-LKKTETQ fragment reproduces is model-dependent
Typical research form	Lyophilized powder in sealed vial	Lyophilized powder in sealed vial
Common reconstitution diluent	Bacteriostatic water	Bacteriostatic water
Regulatory status (US)	Not FDA-approved; sold as research-use-only	Not FDA-approved; sold as research-use-only

Ac-LKKTETQ vs LKKTETQ vs Thymosin Beta-4 — Why the Distinction Matters

Three different chemical species regularly show up under the “TB-500 / thymosin beta-4” umbrella and they should not be treated as interchangeable:

Full-length thymosin beta-4 (Tβ4). The naturally occurring 43-amino-acid peptide (~4.9 kDa). Most peer-reviewed biology of “thymosin beta-4” — actin sequestration, cell migration, angiogenesis, wound-healing models, and the clinical-trial work — was performed on the full-length peptide.
LKKTETQ. The unmodified 7-residue fragment corresponding to residues 17–23 of Tβ4, sometimes called the actin-binding motif. Approximate MW ~846 Da.
Ac-LKKTETQ (TB-500 as commonly sold). The N-terminally acetylated version of the 7-residue fragment. Acetylation adds ~42 Da, giving an approximate MW ~889 Da. This is the chemical form most consistent with the “~889 Da” number cited on many TB-500 product pages.

A study performed on full-length Tβ4 should not automatically be attributed to TB-500, and a mass-spectrometry result should not be interpreted against the wrong reference weight. When reading either the literature or a vendor page, match the reported activity to the exact molecule that was studied or supplied.

How BPC-157 and TB-500 Have Been Studied

Preclinical BPC-157 studies use rodent models of tendon transection, muscle crush, gastric ulcer, and vascular occlusion, delivered by intraperitoneal, oral, or local routes, with histological, functional, and biochemical readouts. Several groups have reported associations between BPC-157 administration and modulation of the VEGFR2 pathway, including VEGFR2 expression/internalization and Akt-eNOS signalling, in specific injury models — described in the literature as an association with pro-angiogenic activity rather than as a single fully mapped mechanism.

Thymosin beta-4 (full-length) has an established biochemical role as an actin-sequestering peptide and has been examined in cardiac ischaemia-reperfusion, corneal and dermal wound closure, and cytoskeletal-remodelling models. Studies on the short Ac-LKKTETQ or LKKTETQ fragment used as a proxy for the Tβ4 active site are smaller in number and more model-dependent, and results from the full-length peptide should not be assumed to transfer directly to the fragment.

BPC-157 vs TB-500: How Their Reported Mechanisms Differ

BPC-157 and TB-500 do not share a mechanism. The BPC-157 literature emphasizes observed associations with VEGFR2-Akt-eNOS signalling, nitric-oxide-related vascular effects, and growth-factor cross-talk in specific injury models — language that reflects experimental findings rather than a single settled mechanism. The Tβ4/TB-500 side of the literature is anchored in actin sequestration as the biochemistry of the full-length peptide, with cell-migration, angiogenesis, and cytoskeletal readouts. The short Ac-LKKTETQ fragment is used as a proxy for the actin-binding motif in a subset of studies, and how completely it reproduces Tβ4 activity depends on the assay.

Are BPC-157 and TB-500 Studied Together?

They are referenced together in preclinical repair research because they are hypothesized to act on complementary pathways. Head-to-head experimental comparisons are relatively limited, and combination products marketed as “repair stacks” pool two mechanisms that are not fully mapped individually — a research design that combines them should include single-agent controls and mechanism-specific readouts if attribution matters.

Handling and Storage — What the Two Peptides Share

Both peptides are typically supplied as lyophilized powders in sealed multi-use vials and dissolve in bacteriostatic water at typical research concentrations. Sealed lyophilized vials are generally stored at -20 °C or -80 °C, and reconstituted vials are refrigerated for short-term use with the balance aliquoted and frozen where the formulation allows. Reconstituted usable life depends on the peptide sequence, formulation, diluent, and freeze–thaw handling — not on the label alone. See How to Reconstitute Research Peptides for the step-by-step protocol and Lyophilized vs Liquid Peptides for the form-level trade-offs.

How to Verify a BPC-157 or TB-500 Vial Before an Experiment

Two verification steps apply regardless of which peptide is on the bench:

Read the batch Certificate of Analysis. Confirm HPLC purity, mass-spectrometric identity, batch/lot reconciliation, and endotoxin data for any cell-based work. See How to Read a Peptide Certificate of Analysis (COA).
Compare the reported mass to the expected mass for the exact chemical species named on the label. BPC-157 should be close to ~1,419 Da. A TB-500 vial labelled Ac-LKKTETQ should be close to ~889 Da; an unmodified LKKTETQ fragment should be close to ~846 Da; full-length Tβ4 is ~4.9 kDa. A large deviation, or a sequence-and-mass pairing that does not match, indicates either the wrong molecule, a modification, or a labelling problem.

Key Takeaways

BPC-157 and TB-500 are distinct research peptides with different origins, sequences, and reported activity.
BPC-157 is a 15-residue peptide (~1,419 Da) with a preclinical literature focused on angiogenesis and cytoprotection.
TB-500 as commonly sold is the acetylated 7-residue fragment Ac-LKKTETQ (~889 Da); the unmodified LKKTETQ is ~846 Da. Neither is the same molecule as full-length thymosin beta-4 (~4.9 kDa).
Findings reported on full-length Tβ4 should not be attributed to TB-500 unless the molecule studied warrants that attribution.
Neither peptide is FDA-approved for therapeutic use; both are sold in research-use-only form.

Frequently Asked Questions

Is BPC-157 stronger than TB-500?

“Stronger” is not a research-meaningful comparison because the two peptides act through different pathways and are measured against different endpoints. A study designed around VEGFR2-related signalling reports different quantities than a study designed around actin dynamics. Compare within a mechanism, not across peptides.

Can BPC-157 and TB-500 be used in the same research protocol?

Yes, and combination studies exist in the preclinical literature. Pooling them makes it harder to attribute an observed effect to a single peptide, so a well-designed protocol includes single-agent controls and mechanism-specific readouts.

Are BPC-157 and TB-500 the same thing?

No. They differ in origin, sequence, molecular weight, and reported mechanism. BPC-157 is a 15-amino-acid peptide (~1,419 Da); TB-500 as most commonly sold is the 7-amino-acid acetylated fragment Ac-LKKTETQ (~889 Da).

Is TB-500 the same as thymosin beta-4?

No. Full-length thymosin beta-4 is a 43-residue peptide (~4.9 kDa). TB-500 is a short fragment (typically Ac-LKKTETQ, ~889 Da) corresponding to residues 17–23 of Tβ4. The two are chemically and biologically distinct, and most peer-reviewed “thymosin beta-4” biology was performed on the full-length peptide, not the fragment.

Do BPC-157 and TB-500 have the same shelf life?

Their handling profiles are similar — both are supplied lyophilized and are generally stable when stored sealed at -20 °C or -80 °C — but real stability depends on the individual batch, the sequence, the formulation, and moisture exposure. The batch COA and manufacturer stability data are the authoritative reference.

What sequence is BPC-157?

The published BPC-157 sequence is GEPPPGKPADDAGLV, a 15-amino-acid partial sequence taken from a fragment of a human gastric-juice protein.

What sequence is TB-500?

TB-500 as commonly sold on the research-supply market is Ac-LKKTETQ, the N-terminally acetylated 7-residue fragment corresponding to residues 17–23 of thymosin beta-4. Some catalogs sell the unmodified LKKTETQ instead. Match the sequence on the vial’s COA to the reported molecular weight before use.

Is BPC-157 or TB-500 FDA-approved?

Neither peptide is FDA-approved for therapeutic use. Both are sold in the United States as research-use-only compounds for in-vitro and preclinical laboratory work.

References

Sikiric P, Seiwerth S, Rucman R, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Curr Pharm Des. Indexed at PubMed.
Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). Indexed at PubMed.
Chang CH, Tsai WC, Hsu YH, Pang JHS. BPC 157 and blood vessels. Curr Pharm Des. Indexed at PubMed.
Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. Indexed at PubMed.
Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. Indexed at PubMed.
Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. Indexed at PubMed.

Research use disclaimer. All peptides sold by AppealLabs are labelled FOR RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION. Content on this page describes preclinical scientific literature only and is not medical advice. Nothing here should be interpreted as diagnosing, treating, curing, or preventing any disease, or as guidance for human use of any peptide.